Dr. Mitchell on Colorectal Cancer Treatment Options

Edith Mitchell, MD, FACP
Published: Tuesday, Sep 10, 2013

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, talks about the growing number of drugs and regimens for patients with colorectal cancer.

Mitchell says the approval of aflibercept adds to the growing list of drugs for patients with colorectal cancer.

In 1996, Mitchell says, 5-gluorouracil was the only drug that showed benefit for patients with metastatic colorectal cancer. Now, as a variety of drugs are available to patients, doctors can strive for the best quality of life possible.

As the number of drugs has increased, so has the improvement of survival for patients with colorectal cancer, Mitchell says.
SELECTED
LANGUAGE
Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, talks about the growing number of drugs and regimens for patients with colorectal cancer.

Mitchell says the approval of aflibercept adds to the growing list of drugs for patients with colorectal cancer.

In 1996, Mitchell says, 5-gluorouracil was the only drug that showed benefit for patients with metastatic colorectal cancer. Now, as a variety of drugs are available to patients, doctors can strive for the best quality of life possible.

As the number of drugs has increased, so has the improvement of survival for patients with colorectal cancer, Mitchell says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x